Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Michael J. Keating; Hagop Kantarjian; Susan O'Brien; Charles Koller; Moshe Talpaz; Jay Schachner; Craig C. Childs; Emil J. Freireich; Kenneth B. McCredie

Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Michael J. Keating, Hagop Kantarjian, Susan O'Brien, Charles Koller, Moshe Talpaz, Jay Schachner, Craig C. Childs, Emil J. Freireich, Kenneth B. McCredie

Research output: Contribution to journal › Article › peer-review

Abstract

Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL. © 1991 by American Society of Clinical Oncology.

Original language	English
Pages (from-to)	44-49
Number of pages	5
Journal	Journal of Clinical Oncology
Volume	9
Issue number	1
Publication status	Published - 1991

Keywords

Adult
Aged
Aged, 80 and over
adverse effects: Antimetabolites, Antineoplastic
Drug Administration Schedule
Female
Humans
drug therapy: Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Neoplasm Staging
Recurrence
Remission Induction
Survival Rate
adverse effects: Vidarabine Phosphate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{bda2594cae6d4e1fac225da82a97f837,

title = "Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia",

abstract = "Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL. {\textcopyright} 1991 by American Society of Clinical Oncology.",

keywords = "Adult, Aged, Aged, 80 and over, adverse effects: Antimetabolites, Antineoplastic, Drug Administration Schedule, Female, Humans, drug therapy: Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Staging, Recurrence, Remission Induction, Survival Rate, adverse effects: Vidarabine Phosphate",

author = "Keating, {Michael J.} and Hagop Kantarjian and Susan O'Brien and Charles Koller and Moshe Talpaz and Jay Schachner and Childs, {Craig C.} and Freireich, {Emil J.} and McCredie, {Kenneth B.}",

year = "1991",

language = "English",

volume = "9",

pages = "44--49",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

AU - Keating, Michael J.

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Koller, Charles

AU - Talpaz, Moshe

AU - Schachner, Jay

AU - Childs, Craig C.

AU - Freireich, Emil J.

AU - McCredie, Kenneth B.

PY - 1991

Y1 - 1991

N2 - Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL. © 1991 by American Society of Clinical Oncology.

AB - Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-11) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL. © 1991 by American Society of Clinical Oncology.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - adverse effects: Antimetabolites, Antineoplastic

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - drug therapy: Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Recurrence

KW - Remission Induction

KW - Survival Rate

KW - adverse effects: Vidarabine Phosphate

M3 - Article

SN - 1527-7755

VL - 9

SP - 44

EP - 49

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 1

ER -

Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

Abstract

Keywords

UN SDGs

Fingerprint

Cite this